EUVIMEDEUVIMED entdecken
Open Access

A STAT1/ETC/GBP1 axis represents a potential therapeutic target for noncommunicable granulomatous skin disease

Manuel Huerta Arana iD, Henning Klapproth iD, Michal A Stanczak iD, Luisa Bopp iD, Karla Witschurke, Robert Seitz iD, Maria Lopéz Martinez, Jan Zamek iD, Sinika Henschke iD, Nisha Rana iD, David O'Sullivan iD, Joy Steinkamp iD und 9 weitere

Science Advances · 29.05.2026 · 12 (22)

DOI: 10.1126/sciadv.aea0773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 29.05.2026. Verfasst von Manuel Huerta Arana und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, University of Cologne, Faculty of Medicine, and University Hospital of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: GTP-Binding Proteins, STAT1 Transcription Factor, Skin Diseases, Granuloma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Forschungsgemeinschaft Bonn Germany, Center for Molecular Medicine Cologne, University of Cologne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Granuloma annulare (GA) and cutaneous sarcoidosis (cSAR) have an overlapping immunopathology, in which the aberrant activation of macrophages by IFN-γ constitutes a central driver. Nevertheless, the molecular understanding in GA and cSAR macrophages remains limited. We reanalyzed single-cell RNA sequencing data of GA and cSAR and performed in vitro experiments with primary human cells showing that oxidative phosphorylation (OXPHOS) is a dominant metabolic pathway in IFN-γ–activated macrophages. Furthermore, we identify an IFN-γ–induced response network in GA and cSAR macrophages, sensitive to electron transport chain (ETC) inhibitors. Guanylate-binding protein 1 (GBP1) was central in controlling IFN-γ–mediated macrophage activation. Meanwhile, inhibition of IFN-γ signaling, ETC complexes, and GBP1 reduced granuloma formation in a human in vitro model. Metformin, a clinically used ETC complex I inhibitor, suppressed IFN-γ activation of macrophages and in vitro granulomas. Together, we suggest that OXPHOS and GBP1 represent druggable targets in granulomatous diseases and that drug repurposing of metformin is a possible strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GTP-Binding ProteinsSTAT1 Transcription FactorSkin DiseasesGranulomaHumansInterferon-gammaMacrophagesSignal TransductionOxidative PhosphorylationMacrophage ActivationSarcoidosisMetformin

Substanzen

Interferon-gammaGTP-Binding ProteinsGBP1 protein, humanSTAT1 Transcription FactorSTAT1 protein, humanMetformin

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, University of Cologne, Faculty of Medicine, and University Hospital of Cologne, Cologne, Germany.
  • Department of Dermatology, Jena University Hospital. Jena, Germany.
  • Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
  • The Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Department of Neuronal Control of Metabolism, Max Planck Institute for Metabolism Research, Cologne, Germany.
  • Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD), Cologne, Germany.

ORCID-Profile: Manuel Huerta Arana, Henning Klapproth, Michal A Stanczak, Luisa Bopp, Robert Seitz, Jan Zamek, Sinika Henschke, Nisha Rana, David O'Sullivan, Joy Steinkamp, Jan-Wilm Lackmann, William Damsky, Esther von Stebut, David E Sanin, Paola Zigrino, Ramon I Klein Geltink, Edward J Pearce, Erika L Pearce, Mario Fabri

Förderung

  • Deutsche Forschungsgemeinschaft
  • Deutsche Forschungsgemeinschaft Bonn Germany
  • Center for Molecular Medicine Cologne, University of Cologne
  • Koeln Fortune Program/Faculty of Medicine, University of Cologne
  • Michael Smith Health Research BC Scholar Award
  • Max Planck Society

Zitieren

APA

Huerta Arana, M., Klapproth, H., Stanczak, M. A., Bopp, L., Witschurke, K., Seitz, R., Lopéz Martinez, M., Zamek, J., Henschke, S., Rana, N., O'Sullivan, D., Steinkamp, J., Lackmann, J. W., Damsky, W., von Stebut, E., Sanin, D. E., Zigrino, P., Klein Geltink, R. I., Pearce, E. J., …, & Fabri, M. (2026). A STAT1/ETC/GBP1 axis represents a potential therapeutic target for noncommunicable granulomatous skin disease. Science Advances, 12(22). https://doi.org/10.1126/sciadv.aea0773

Vancouver

Huerta Arana M, Klapproth H, Stanczak MA, Bopp L, Witschurke K, Seitz R, et al. A STAT1/ETC/GBP1 axis represents a potential therapeutic target for noncommunicable granulomatous skin disease. Science Advances. 2026;12(22). doi:10.1126/sciadv.aea0773

BibTeX
@article{HuertaArana2026,
  author = {Huerta Arana, Manuel and Klapproth, Henning and Stanczak, Michal A and Bopp, Luisa and Witschurke, Karla and Seitz, Robert and Lopéz Martinez, Maria and Zamek, Jan and Henschke, Sinika and Rana, Nisha and O'Sullivan, David and Steinkamp, Joy and Lackmann, Jan-Wilm and Damsky, William and von Stebut, Esther and Sanin, David E and Zigrino, Paola and Klein Geltink, Ramon I and Pearce, Edward J and Pearce, Erika L and Fabri, Mario},
  title = {A STAT1/ETC/GBP1 axis represents a potential therapeutic target for noncommunicable granulomatous skin disease},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {22},
  doi = {10.1126/sciadv.aea0773}
}
Kostenlos starten →